Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck May Face $2 Bil. Tax Bill; Medco Transactions Subject Of IRS Notice

Executive Summary

Merck is facing a potential $2 bil. back tax liability arising out of a "partnership transaction" tied to the 1993 Medco acquisition

You may also be interested in...



GSK Contests $5.2 Bil. Tax Bill After IRS Decision On Zantac Transfer Pricing

GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest

MERCK MARKET SHARE ON MEDCO FORMULARIES REACHES 12%, UP FROM 10%; MERCK WILL NOT BROADEN PRODUCT LINE TO MAINTAIN MARKET SHARE, CEO GILMARTIN TELLS NYSSA

Merck products have climbed to a 12% share of Medco formulary product sales, Merck Chairman and CEO Ray Gilmartin told a meeting of the New York Society of Security Analysts Nov. 29.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel